Immunic (IMUX) Projected to Announce Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($1.1648) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Immunic (NASDAQ:IMUX) last released its earnings results on Wednesday, May 13th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.37). On average, analysts expect Immunic to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Immunic Trading Down 0.4%

Shares of NASDAQ:IMUX opened at $14.05 on Wednesday. The stock’s 50-day moving average price is $14.34 and its two-hundred day moving average price is $11.61. Immunic has a 12-month low of $5.06 and a 12-month high of $15.84. The firm has a market cap of $191.36 million, a price-to-earnings ratio of -2.52 and a beta of 1.41.

Institutional Investors Weigh In On Immunic

Institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC acquired a new stake in shares of Immunic in the fourth quarter worth $2,337,000. Millennium Management LLC lifted its holdings in shares of Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after acquiring an additional 2,888,829 shares in the last quarter. Laurion Capital Management LP lifted its holdings in shares of Immunic by 106.3% during the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after acquiring an additional 2,000,000 shares in the last quarter. Marshall Wace LLP boosted its position in Immunic by 91.2% during the 4th quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock worth $541,000 after purchasing an additional 486,468 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Immunic during the 3rd quarter worth $239,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IMUX has been the subject of a number of research analyst reports. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Wolfe Research assumed coverage on shares of Immunic in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, May 4th. Wall Street Zen lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Sunday, April 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target (up from $5.00) on shares of Immunic in a research note on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $47.57.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.